Prestige Consumer Healthcare Inc. (PBH) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects a mix of positive and negative elements. Basic financial performance is challenged by supply chain issues and declining revenue guidance, while product development and market strategy show potential for recovery and growth. Expenses are manageable with expected cash flow, but the lack of clear guidance and uncertainties in specific areas like Clear Eyes recovery and e-commerce order patterns contribute to a neutral sentiment. Given the market cap, the stock is likely to experience minor fluctuations, resulting in a neutral prediction for the next two weeks.
Key Financial Performance
Revenue Q2 revenue of $274.1 million declined 3.4% from $283.8 million in the prior year. The decline was mainly due to lower eye and ear care category sales, largely because of Clear Eyes supply constraints, along with lower cough and cold category sales.
Gross Margin Total company gross margin of 55.7% in the first 6 months was up 60 basis points versus the prior year. This improvement was attributed to better cost management and product mix.
Adjusted EPS Adjusted EPS of $1.07 in Q2 was down slightly from $1.09 in the prior year. The decline was primarily offset by favorable timing of advertising and marketing (A&M) expenses, as well as improvements in interest expense and share count.
Free Cash Flow Free cash flow for the first half was $133.6 million, up approximately 10% versus the prior year. This increase was driven by strong financial performance and efficient cash management.
Leverage Ratio The leverage ratio remained stable at 2.4x, supported by consistent business performance and cash flow generation.
International Segment Revenue International segment revenues increased 2.7% versus the prior year for the first 6 months, driven by higher Hydralyte sales.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DenTek brand expansion: DenTek brand is expanding its reach in the dental care market with a focus on dental guards, which represent over half of the brand's revenue. The brand has achieved over 50% market share in the category, supported by innovative marketing campaigns like the Fantasy Guards campaign.
E-commerce growth: Double-digit e-commerce consumption growth continues, driven by long-term investments and successful participation in large-scale e-commerce sales events.
International OTC segment growth: International OTC segment revenues increased by 2.7% in the first half, supported by higher Hydralyte sales.
Clear Eyes supply chain improvement: Efforts are underway to improve Clear Eyes supply in the second half of fiscal 2026, which is critical to meeting the full-year revenue forecast.
Free cash flow generation: Generated $134 million in free cash flow in the first half, up 10% year-over-year, with a full-year target of $245 million or more.
Share repurchase program: Repurchased 1.6 million shares for approximately $110 million in the first half, with plans to continue opportunistic repurchases.
Acquisition of Pillar5: The company plans to acquire its eye care manufacturer, Pillar5, for approximately $100 million, with the transaction expected to close in Q3.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Supply Chain Constraints: The company is facing supply chain constraints, particularly affecting the Clear Eyes product line, which has led to lower sales in the eye and ear care category. This issue is expected to impact Q3 revenues as well.
High Inflation: High inflation is contributing to an uncertain business environment, potentially affecting costs and consumer purchasing behavior.
Geopolitical Events: Geopolitical events are adding to the uncertainty in the business environment, which could have various impacts on operations and financial performance.
E-commerce Order Variability: The company has experienced variability in e-commerce customer order patterns, which has impacted revenue timing and could continue to create forecasting challenges.
Tariff Costs: The company faces potential tariff costs of approximately $5 million for the year, although exposure is described as modest.
Clear Eyes Supply Chain Recovery: While improvements in Clear Eyes supply are expected in the second half, delays in inventory availability have already impacted sales and could continue to do so in the near term.
Advertising and Marketing Timing: The timing of advertising and marketing expenses has created fluctuations in financial performance, with Q3 expected to have the highest spend rate of the year.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: For fiscal '26, the company anticipates revenues of $1.1 billion to $1.115 billion, with organic growth down approximately 1.5% to 3% versus the prior year. For Q3, revenue is expected to be approximately $282 million, down versus the prior year due to Clear Eyes inventory timing and e-commerce retailer order adjustments.
Gross Margin Projections: The company expects a gross margin of 56.5% for the year, with Q3 gross margin projected at approximately 56%.
Adjusted EPS: The company anticipates adjusted EPS of $4.54 to $4.58 for the full year, which is the higher end of the prior range, and Q3 EPS of $1.14.
Free Cash Flow: The company maintains its outlook for full-year free cash flow of $245 million or more.
Clear Eyes Supply Improvement: The company is on track to improve Clear Eyes supply in the second half of fiscal '26, which underpins the full-year forecast.
E-commerce Growth: The company continues to experience double-digit year-over-year consumption growth in the e-commerce business, driven by long-term investments.
International OTC Segment Growth: The company maintains confidence in its long-term algorithm for 5% annual segment revenue growth in the International OTC segment.
Capital Deployment: The company plans to continue opportunistic share repurchases and anticipates the strategic acquisition of its eye care manufacturer, Pillar5, for approximately $100 million in Q3.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: In Q2, the company repurchased over 1.1 million shares. For the first 6 months of fiscal '26, the company repurchased 1.6 million shares for approximately $110 million. The majority of these repurchases were opportunistic during Q2, and the company expects to continue share repurchases through the remainder of the year.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide an update on the Clear Eyes supply chain and its impact on shipments and shelf space?
A:The company has been working on improving the Clear Eyes supply chain by bringing on two new suppliers and upgrading the Pillar5 high-speed line. While there has been a significant reduction in shelf space due to supply constraints, the company expects sequential improvement in Q3 and Q4. Recovery of shelf space will take time as retailers need to regain confidence in the company's ability to sustain service levels.
Q:What are your expectations for the cold/cough season, both domestically and internationally?
A:The cold and flu category is not a significant part of the company's business, contributing high single digits. The international business, particularly in the Southern Hemisphere, performed well. Domestically, the company is waiting to see how illness levels play out during the Thanksgiving to New Year's timeframe and finds it too early to predict.
Q:How would you characterize the health of retailer inventories in the U.S. outside of the e-commerce channel?
A:Retailer inventories in the U.S. outside of e-commerce have been steady and predictable. The company has not seen significant impacts in these channels, unlike broader CPG categories where inventory reductions are more common.
Q:Why was women's health down in North America this quarter, and what is the broader trend?
A:Women's health was down this quarter due to unusual order patterns and comparisons from last year, including changes in product offerings. However, over the last three to four quarters, women's health has shown growth, and the company remains confident in its long-term positioning.
Q:What is your perspective on the macro environment and its impact on your business?
A:The macro environment shows slowing consumer trends, but the company's needs-based products are somewhat insulated. The company has broad offerings and multiple price points, which help capture consumers despite economic pressures. No meaningful impact on the business outlook has been observed.
Q:What is driving the difference between the high and low end of your sales guidance range?
A:The primary driver is the recovery of the eye care segment, particularly Clear Eyes. The rest of the business is performing as expected, with international growth and normal seasonality contributing to the outlook.
Q:How are you approaching capital allocation, and has recent M&A activity influenced your strategy?
A:The company prioritizes M&A and is sitting on historically low leverage levels. It expects to generate over $1 billion in cash flow over the next four years. Recent M&A activity has not changed the company's strategy, and it remains disciplined in pursuing opportunities that offer long-term growth and value creation.
Q:What are the consumption trends in North America excluding Clear Eyes, and how is the company performing overall?
A:Excluding Clear Eyes and adjusting for FX, total company sales are up 2.5% over the trailing twelve months, in line with long-term expectations. International sales are up 5%, and North America is up about 1%. Strong performance has been noted in GI and women's health categories.
Q:What are the expectations for Clear Eyes recovery in terms of shelf space and supply chain improvements?
A:The company expects to have all supply chain improvements for Clear Eyes in place by the end of the fiscal year, including two new suppliers and a high-speed line at Pillar5. Recovery of shelf space will depend on retailer confidence and may take two resets. Marketing investments will be needed to regain consumer interest.
Q:What is driving the expected improvement in gross margin in the second half of the year?
A:The improvement is driven by cost savings, mix benefits, and the resolution of temporary costs such as dual warehousing in Australia. A significant step-up is expected in Q4 due to the timing of cost savings.
Q:What is causing variability in e-commerce order patterns, and how is the company addressing it?
A:E-commerce order patterns are unpredictable, and the company does not receive insights from its e-commerce customers. The focus is on maintaining high service levels and growing consumption and market share.
Q:Are there plans to bring more production in-house to avoid supply chain issues like those experienced with Clear Eyes?
A:The company has no plans to bring more production in-house beyond the acquisition of Pillar5 for sterile eye care. The rest of the portfolio has sufficient external capacity, and no other significant changes are expected.
Q:Will the company need to carry higher inventory levels going forward?
A:The company may increase safety stock for certain brands to ensure customer service but does not anticipate a material change in overall inventory levels.
Q:How will marketing investments change once Clear Eyes supply issues are resolved?
A:Marketing investments will be reallocated to Clear Eyes as supply improves, but the overall A&M spending ratio is not expected to increase. The company will continue to evaluate the right level of investment based on opportunities and returns.
Q:Is private label competition impacting the company's market share?
A:Private label competition has not significantly impacted the company's market share. The company operates in different spaces than private label players, such as needs-based products.
Q:What is the status of the Pillar5 acquisition, and how will it impact operations?
A:The Pillar5 acquisition is expected to close in Q3. The company has been deeply involved with Pillar5 and plans to run it for the long term to address the scarcity of sterile eye care capacity. The acquisition will primarily be financed with cash on hand.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear answer on the timing and extent of Clear Eyes shelf space recovery, stating it depends on retailer confidence and may take two resets. Additionally, they did not provide specific details on how e-commerce order variability will be managed or any concrete plans for increasing inventory levels.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Clear Eyes
DenTek
Eyes supply
Guards
Slide
brand building
campaign
care category
category sale
commerce
constraint
consumption
event
eye care
guard
interest expense
leverage ratio
market share
marketing
measure
month
order
outlook
portfolio
presentation today
product offering
result
revenue
risk
slide presentation
tariff
tax rate
timing factor
variability
PBH Transcript
Prestige Consumer Healthcare Inc. (PBH) Q4 2026 Earnings Call Transcript
Unknown5-14
The earnings call reveals positive financial results, with revenue, gross margin, and net income showing year-over-year growth. However, supply chain constraints and high inflation pose significant risks. The absence of strategic initiatives and operational updates, combined with unclear management responses in the Q&A, tempers enthusiasm. The market cap indicates moderate sensitivity to news, suggesting a neutral stock price movement in the short term.
Prestige Consumer Healthcare Inc. (PBH) Q3 2026 Earnings Call Transcript
Unknown2-5
The earnings call highlights mixed signals: strong e-commerce growth and product launches are positive, but inventory destocking and uncertain guidance create concerns. While management's optimism about Clear Eyes supply and stable margins is reassuring, the lack of specific guidance and volatility in retailer order patterns are drawbacks. Given the market cap, a neutral stock price movement is likely as positive and negative factors balance out.
Prestige Consumer Healthcare Inc. (PBH) Q2 2026 Earnings Call Transcript
Unknown11-6
The earnings call summary reflects a mix of positive and negative elements. Basic financial performance is challenged by supply chain issues and declining revenue guidance, while product development and market strategy show potential for recovery and growth. Expenses are manageable with expected cash flow, but the lack of clear guidance and uncertainties in specific areas like Clear Eyes recovery and e-commerce order patterns contribute to a neutral sentiment. Given the market cap, the stock is likely to experience minor fluctuations, resulting in a neutral prediction for the next two weeks.
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 18th Annual Global Consumer Staples Conference 2025 Transcript
Neutral9-5
PBH Slides
PBH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
